A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES… (NCT07459634) | Clinical Trial Compass
Not Yet RecruitingPhase 2
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
United States50 participantsStarted 2026-04-25
Plain-language summary
The purpose of this study is to evaluate the efficacy and safety of lurbinectedin in combination with durvalumab for the treatment of participants with extensive stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first line (1L) induction therapy.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Participant has histologically or cytologically confirmed ES-SCLC (per Veterans Administration Lung Study Group staging system).
✓. Participant has received 4 cycles of definitive platinum-based chemotherapy with durvalumab
✓. Has Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
✓. Must have a life expectancy of ≥ 12 weeks as assessed by the treating physician.
✓. Adequate hematologic and end-organ function for at least 7 days prior to dosing.
✕. Presence or history of Central Nervous System (CNS) metastases
✕. History of allogeneic organ transplantation.
✕. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on the screening chest CT scan.